Andreas Meyerhans
Overview
Explore the profile of Andreas Meyerhans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
2067
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marcos-Villar L, Perdiguero B, Lopez-Bravo M, Zamora C, Sin L, Alvarez E, et al.
Emerg Microbes Infect
. 2024 Aug;
13(1):2387906.
PMID: 39087555
Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies....
2.
Casella V, Cebollada Rica P, Argilaguet J, Vidal E, Gonzalez-Cao M, Guerri-Fernandez R, et al.
Viruses
. 2024 May;
16(5).
PMID: 38793680
Immunotherapy with checkpoint inhibitors, albeit commonly used against tumors, is still at its infancy against chronic virus infections. It relies on the reinvigoration of exhausted T lymphocytes to eliminate virus-infected...
3.
Marcos-Villar L, Perdiguero B, Anthiya S, Borrajo M, Lou G, Franceschini L, et al.
NPJ Vaccines
. 2024 May;
9(1):84.
PMID: 38762608
No abstract available.
4.
Marcos-Villar L, Perdiguero B, Anthiya S, Borrajo M, Lou G, Franceschini L, et al.
NPJ Vaccines
. 2024 Mar;
9(1):53.
PMID: 38448450
Vaccines based on mRNA technology have revolutionized the field. In fact, lipid nanoparticles (LNP) formulated with mRNA are the preferential vaccine platform used in the fight against SARS-CoV-2 infection, with...
5.
Esteban I, Pastor-Quinones C, Usero L, Aurrecoechea E, Franceschini L, Esprit A, et al.
Vaccines (Basel)
. 2024 Jan;
12(1).
PMID: 38250827
The COVID-19 pandemic has brought significant changes and advances in the field of vaccination, including the implementation and widespread use of encapsidated mRNA vaccines in general healthcare practice. Here, we...
6.
Sistere-Oro M, Du J, Wortmann D, Filippi M, Canas-Ruano E, Arrieta-Aldea I, et al.
J Med Virol
. 2023 Dec;
96(1):e29317.
PMID: 38150509
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell...
7.
Casella V, Domenjo-Vila E, Esteve-Codina A, Pedragosa M, Cebollada Rica P, Vidal E, et al.
Cell Death Dis
. 2023 Dec;
14(12):838.
PMID: 38110339
Acute infection and chronic infection are the two most common fates of pathogenic virus infections. While several factors that contribute to these fates are described, the critical control points and...
8.
Prenafeta A, Bech-Sabat G, Moros A, Barreiro A, Fernandez A, Canete M, et al.
iScience
. 2023 Jul;
26(7):107224.
PMID: 37502366
SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still...
9.
Moros A, Prenafeta A, Barreiro A, Perozo E, Fernandez A, Canete M, et al.
Vaccine
. 2023 Jul;
41(35):5072-5078.
PMID: 37460353
The continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an...
10.
Kobayashi-Ishihara M, Frazao Smutna K, Alonso F, Argilaguet J, Esteve-Codina A, Geiger K, et al.
Commun Biol
. 2023 May;
6(1):487.
PMID: 37165099
Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood. Here we describe the Schlafen...